JP2001509787A - トリプターゼ活性に関わる病気を処置するための新規の化合物及び組成物 - Google Patents

トリプターゼ活性に関わる病気を処置するための新規の化合物及び組成物

Info

Publication number
JP2001509787A
JP2001509787A JP50913698A JP50913698A JP2001509787A JP 2001509787 A JP2001509787 A JP 2001509787A JP 50913698 A JP50913698 A JP 50913698A JP 50913698 A JP50913698 A JP 50913698A JP 2001509787 A JP2001509787 A JP 2001509787A
Authority
JP
Japan
Prior art keywords
alkylene
twenty
compound
hetero
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP50913698A
Other languages
English (en)
Japanese (ja)
Inventor
マーク デナー，ジェフレイ
イー―リン クオ，エライン
ドゥアン ライス，ケン
リュウェン ワン，ビビアン
ベス ヤング，ウェンディー
Original Assignee
アクシス ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクシス ファーマシューティカルズ，インコーポレイティド filed Critical アクシス ファーマシューティカルズ，インコーポレイティド
Publication of JP2001509787A publication Critical patent/JP2001509787A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP50913698A 1996-07-30 1997-07-30 トリプターゼ活性に関わる病気を処置するための新規の化合物及び組成物 Pending JP2001509787A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US60/023,139 1996-07-30
US89577297A 1997-07-17 1997-07-17
US08/895,772 1997-07-17
PCT/US1997/013422 WO1998004537A1 (fr) 1996-07-30 1997-07-30 Nouveaux composes et compositions servant a traiter des maladies associees a l'activite de tryptase

Publications (1)

Publication Number Publication Date
JP2001509787A true JP2001509787A (ja) 2001-07-24

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50913698A Pending JP2001509787A (ja) 1996-07-30 1997-07-30 トリプターゼ活性に関わる病気を処置するための新規の化合物及び組成物

Country Status (17)

Country Link
EP (1) EP0934293A1 (fr)
JP (1) JP2001509787A (fr)
KR (1) KR20000029679A (fr)
CN (1) CN1073103C (fr)
AU (1) AU733621B2 (fr)
CA (1) CA2262542A1 (fr)
CZ (1) CZ29799A3 (fr)
EE (1) EE9900036A (fr)
FI (1) FI990171A (fr)
HU (1) HUP0003267A3 (fr)
LV (1) LV12291B (fr)
NO (1) NO990433L (fr)
NZ (1) NZ333713A (fr)
PL (1) PL331465A1 (fr)
SI (1) SI9720047A (fr)
SK (1) SK8599A3 (fr)
WO (1) WO1998004537A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003514792A (ja) * 1999-11-18 2003-04-22 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト トリプターゼインヒビターとしてのビス−塩基性化合物、それらの調製方法及び医薬組成物としてのそれらの使用
WO2018207950A1 (fr) * 2017-05-12 2018-11-15 横山　茂之 Modificateur de composé de liaison de gpcr de classe a

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
WO1999040083A2 (fr) * 1998-02-06 1999-08-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de la tryptase
US6613769B1 (en) * 1998-02-06 2003-09-02 Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. Tryptase inhibitors
WO2000014097A2 (fr) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouvelles pyranoses
ATE279398T1 (de) 1999-08-10 2004-10-15 Altana Pharma Ag Diazocindionderivate und ihre verwendung als tryptase inhibitoren
US6960588B1 (en) 1999-09-14 2005-11-01 Altana Pharma Ag Tryptase inhibitors
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
US6815557B2 (en) 1999-12-20 2004-11-09 Altana Pharma Ag Tryptase inhibitors
US7015325B2 (en) * 1999-12-20 2006-03-21 Altana Pharma Ag Tryptase inhibitors
WO2002060895A1 (fr) * 2001-01-31 2002-08-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Derives de diazocine et leur utilisation en tant qu'inhibiteurs de tryptase
ES2287268T3 (es) 2001-02-21 2007-12-16 Nycomed Gmbh Inhibidores de triptasa.
ATE349427T1 (de) 2001-02-21 2007-01-15 Altana Pharma Ag Tryptaseinhibitoren
JP2004525926A (ja) * 2001-03-15 2004-08-26 アルタナ　ファルマ　アクチエンゲゼルシャフト トリプターゼ阻害剤
WO2002074732A2 (fr) * 2001-03-15 2002-09-26 Altana Pharma Ag Inhibiteurs de la tryptase
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100392A1 (fr) 2001-06-11 2002-12-19 Xenoport, Inc. Formes de dosage de promedicaments a faible toxicite a base d'analogues du gaba, administrees par voie orale
WO2002102771A1 (fr) 2001-06-19 2002-12-27 Altana Pharma Ag Inhibiteurs de tryptase
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
KR101335118B1 (ko) * 2008-12-19 2013-12-05 메르츠 파마 게엠베하 운트 코. 카가아 비만 세포 매개 질환의 치료를 위한 １-아미노-알킬시클로헥산 유도체
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
EP0688337A1 (fr) * 1993-03-12 1995-12-27 Arris Pharmaceutical Corporation Compositions et procedes pour le traitement d'affections inflammatoires immunoresultantes
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
DE69514798D1 (de) * 1994-06-01 2000-03-02 Axys Pharm Inc Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten
SI9520101A (en) * 1994-09-23 1997-12-31 Arris Pharm Corp Compositions and methods for treating mast-cell inflammatory condition
CN1071751C (zh) * 1995-03-24 2001-09-26 阿克西斯制药公司 可逆蛋白酶抑制剂
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003514792A (ja) * 1999-11-18 2003-04-22 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト トリプターゼインヒビターとしてのビス−塩基性化合物、それらの調製方法及び医薬組成物としてのそれらの使用
WO2018207950A1 (fr) * 2017-05-12 2018-11-15 横山　茂之 Modificateur de composé de liaison de gpcr de classe a
JPWO2018207950A1 (ja) * 2017-05-12 2020-04-09 国立研究開発法人理化学研究所 クラスａ ｇｐｃｒ結合性化合物改変体
JP7373191B2 (ja) 2017-05-12 2023-11-02 国立研究開発法人理化学研究所 クラスａ ｇｐｃｒ結合性化合物改変体

Also Published As

Publication number Publication date
NZ333713A (en) 2000-12-22
EP0934293A1 (fr) 1999-08-11
HUP0003267A2 (hu) 2001-06-28
FI990171A0 (fi) 1999-01-29
FI990171A (fi) 1999-03-23
PL331465A1 (en) 1999-07-19
EE9900036A (et) 1999-08-16
KR20000029679A (ko) 2000-05-25
CN1073103C (zh) 2001-10-17
SI9720047A (sl) 1999-08-31
AU733621B2 (en) 2001-05-17
CA2262542A1 (fr) 1998-02-05
HUP0003267A3 (en) 2002-02-28
WO1998004537A1 (fr) 1998-02-05
AU3967097A (en) 1998-02-20
LV12291B (en) 2000-04-20
SK8599A3 (en) 2000-03-13
NO990433L (no) 1999-03-25
CZ29799A3 (cs) 1999-06-16
LV12291A (lv) 1999-06-20
CN1226892A (zh) 1999-08-25
NO990433D0 (no) 1999-01-29

Similar Documents

Publication Publication Date Title
JP2001509787A (ja) トリプターゼ活性に関わる病気を処置するための新規の化合物及び組成物
CA2409827C (fr) Derives d'arylmethylamine utilises comme inhibiteurs de la tryptase
JP4563800B2 (ja) ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン
US6511993B1 (en) Metalloprotease inhibitors
JP4326468B2 (ja) ヒスタミンｈ３アンタゴニストとして有用なインドール誘導体
DE69633983T2 (de) Inhibitoren von mikrosomalem triglycerid-transfer-protein und verfahren
RU2638537C2 (ru) Ингибирование ферментов
JP2003501388A (ja) メタロプロテアーゼ阻害剤
JP4796732B2 (ja) トリプターゼ阻害剤として使用するためのアリールメチルアミン誘導体
JP2002536373A (ja) スルファメトヒドロキサム酸メタロプロテアーゼ阻害剤
AU752064B2 (en) Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity
JP2001513749A (ja) ブラジキニン作動薬としてのキノリンおよびベンズイミダゾール誘導体
JP2003509417A (ja) トリプターゼインヒビター
JP2000509066A (ja) キノリン誘導体、それらの製造方法、および医薬としてのそれらの用途
JP2003524598A (ja) 新規ピラノセン
JP2013515725A (ja) ［４［４−（５−アミノメチル−２−フルオロ−フェニル）−ピペリジン−１−イル］−（１ｈ−ピロロ−ピリジン−イル）−メタノン類及びその合成
US6251919B1 (en) Heterocyclic substituted aniline calcium channel blockers
US6562854B2 (en) Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
DE60021521T4 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen
JP2007008913A (ja) ピペリジン化合物およびその製法
US20040192734A1 (en) 4-(3-aminomethylphenyl)piperidin-1-yl]-[5-(2-fluorophenylethynyl)furan-2-yl]-methanone as an inhibitor of mast cell tryptase
CA2784891A1 (fr) Promedicaments de [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones et leur synthese
LT4587B (lt) Nauji junginiai ir kompozicijos, skirti gydyti ligas, susijusias su triptazės aktyvumu
KR20000069063A (ko) Ｎ-(이미다졸릴부틸)벤젠설폰아미드 유도체, 이들의 제법 및치료에의 응용
MXPA99001105A (en) Novel compounds and compositions for treating diseases associated with tryptase activity